Strategic Partnerships PharmaJet is actively forming collaborations with regional health networks and manufacturers, such as AFENET and EVA Pharma, indicating a clear entrance path for needle-free delivery solutions in Africa and Egypt—a potential channel for joint implementations and co-marketing opportunities.

Global Regulatory Ready With FDA 510(k), CE Mark, and WHO PQS certifications on both Stratis and Tropis systems, PharmaJet products are positioned for rapid deployment in international immunization programs, enabling rapid customer onboarding in public health and large-scale vaccination projects.

Vaccine & Therapeutic Focus Recent collaborations in HIV therapeutic DNA vaccines and DNA cancer vaccine trials highlight opportunities to position needle-free delivery as a differentiator for advanced vaccines and personalized therapies, appealing to research institutions and biopharma partners seeking improved immunogenicity.

Public Health Impact Commercial availability of Stratis and Tropis systems for intramuscular, subcutaneous, and intradermal delivery supports scalable immunization programs, suggesting sales opportunities with government health agencies, NGOs, and global health initiatives pursuing efficient and patient-friendly injections.

Engagement & Events Active participation in industry events such as PODD, World Vaccine Congress, and BIO 2025, along with public announcements of partnerships, indicates ongoing visibility and opportunities to schedule senior briefings, demonstrations, and pilot programs with prospective customers seeking needle-free delivery solutions.